Looney Lab
Therapeutic Targeting of Senescent Cells in Lupus
Targeting senescent cells in patients with lupus presents a potential novel approach to disease management and improved clinical outcomes. While it is known that lupus patients possess cells with a senescence-like phenotype, it is unknown whether these cells would respond to available senolytic drugs. Studying the effects of these drugs in vitro using patient and lupus mouse model samples will further fundamental insights into the potential role of senolytic drugs in the treatment of lupus.

Richard John Looney, M.D.
Principal Investigator
Publications
- A Phenotypically Distinct Human Th2 Cell Subpopulation Is Associated With Development of Allergic Disorders in Infancy.; Allergy. 2025 Feb 03.
- Human milk antibodies to global pathogens reveal geographic and interindividual variations in IgA and IgG.; The Journal of clinical investigation; Vol 134(15). 2024 Jun 11.
- Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial.; The Lancet. Rheumatology. 2024 Jan 29.
- B Cell-Directed Therapy in Autoimmunity.; Annual review of immunology. 2023 Nov 27.
Affiliations
News
January 15, 2025
ROChester Stimulating Access to Research during Residency (ROC StARR) Health and Immune Function Across the Lifespan to Begin July 1st
January 6, 2025
Jennifer Anolik Named Chief of Allergy, Immunology and Rheumatology Division
December 13, 2024
Ilana Abeles Receives Clinical Trial Investigator Award
December 11, 2024
AIR Faculty Shine at ACR Meeting
October 4, 2024
Dr. Jennifer Anolik Delivers Keynote Address
Contact Us
Looney Lab
601 Elmwood Ave/Box 695
Rochester, NY 14642